This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-15. Anything still debated is marked as such rather than presented as settled.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally considered hygroscopic and may degrade faster in aqueous solution than in dry powder form. Phosphate esters can hydrolyze under strongly acidic or alkaline conditions, and elevated temperatures accelerate such reactions. For storage, sealed containers at low temperature with desiccant are typical laboratory practices. Stability-indicating methods should separate NMN from its degradation products, including nicotinamide and nicotinamide riboside, so that purity loss can be tracked accurately.
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
| Property | Value | Notes |
|---|---|---|
| Common analytical method | HPLC-UV or LC-MS/MS | LC-MS/MS offers higher sensitivity for complex matrices. |
| Typical purity specification | ≥95% by HPLC | Values vary by supplier and product grade. |
| Storage temperature | −20 °C or lower | Desiccated and protected from light; avoid repeated warming. |
| Water solubility | Soluble | Aqueous solutions may be acidic and should be prepared fresh when possible. |
| Common synonyms | Nicotinamide mononucleotide; β-NMN | The β anomer is the naturally occurring form. |
Quality control for NMN materials typically includes appearance, assay, impurity profile, residual solvents, heavy metals, and microbial limits. A certificate of analysis summarizes specified tests, but the underlying methods and laboratory accreditation matter. Regulatory treatment varies by country; NMN is sold as a dietary supplement in some markets, while other jurisdictions restrict its use in foods or classify it differently. Independent verification can reduce risks of mislabeling or substitution. Questions remain about how product purity, storage history, and formulation affect delivered dose in humans.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
NMN is a polar, water-soluble nucleotide. In solid form it is usually a white to off-white powder. The compound is sensitive to heat, light, moisture, and extremes of pH, and aqueous solutions tend to degrade faster than dry material. Recommended storage for research samples is typically -20 °C or below in a sealed, desiccated container protected from light. Repeated freeze-thaw cycles should be avoided, and these handling practices help maintain identity and purity during laboratory use.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Many jurisdictions require operators be certified or licensed to work with chainsaws. Injury can also result if the chain breaks during operation due to poor maintenance or attempting to cut inappropriate materials. Gasoline-powered chainsaws expose operators to harmful carbon monoxide gas, especially indoors or in partially enclosed outdoor areas. Drop starting, or turning on a chainsaw by dropping it with one hand while pulling the starting cord with the other, is a safety violation in most states in the U.S. Keeping both hands on the saw for stability is essential for safe chainsaw use. Safe and effective chainsaw and crosscut use on federally administered public lands within the United States has been codified since 2016 in the Final Directive for National Saw Program issued by the United States Forest Service, which specifies the training, testing, and certification process for employees and unpaid volunteers who operate chainsaws within public lands.
Such machines are used for freezing oocytes, skin, blood products, embryo, sperm, stem cells, and general tissue preservation in hospitals, veterinary practices, and research labs. The number of live births from 'slow frozen' embryos is some 300,000 to 400,000 or 20% of the estimated 3 million in vitro fertilized births. Dr Christopher Chen, Australia, reported the world’s first pregnancy using slow-frozen oocytes from a British controlled-rate freezer in 1986. Cryosurgery (intended and controlled tissue destruction by ice formation) was carried out by James Arnott in 1845 in an operation on a patient with cancer.
=== EC 2.3.1: Transferring groups other than amino-acyl groups === EC 2.3.1.1: amino-acid N-acetyltransferase EC 2.3.1.2: imidazole N-acetyltransferase EC 2.3.1.3: glucosamine N-acetyltransferase EC 2.3.1.4: glucosamine-phosphate N-acetyltransferase EC 2.3.1.5: arylamine N-acetyltransferase EC 2.3.1.6: choline O-acetyltransferase EC 2.3.1.7: carnitine O-acetyltransferase EC 2.3.1.8: phosphate acetyltransferase EC 2.3.1.9: acetyl-CoA C-acetyltransferase EC 2.3.1.10: hydrogen-sulfide S-acetyltransferase EC 2.3.1.11: thioethanolamine S-acetyltransferase EC 2.3.1.12: dihydrolipoyllysine-residue acetyltransferase EC 2.3.1.13: glycine N-acyltransferase EC 2.3.1.14: glutamine N-phenylacetyltransferase EC 2.3.1.15: glycerol-3-phosphate O-acyltransferase EC 2.3.1.16: acetyl-CoA C-acyltransferase EC 2.3.1.17: aspartate N-acetyltransferase EC 2.3.1.18: galactoside O-acetyltransferase EC 2.3.1.19: phosphate butyryltransferase EC 2.3.1.20: diacylglycerol O-acyltransferase EC 2.3.1.21: carnitine O-palmitoyltransferase EC 2.3.1.22: 2-acylglycerol O-acyltransferase EC 2.3.1.23: 1-acylglycerophosphocholine O-acyltransferase EC 2.3.1.24: sphingosine N-acyltransferase EC 2.3.1.25: plasmalogen synthase EC 2.3.1.26: sterol O-acyltransferase EC 2.3.1.27: cortisol O-acetyltransferase EC 2.3.1.28: chloramphenicol O-acetyltransferase EC 2.3.1.29: glycine C-acetyltransferase EC 2.3.1.30: serine O-acetyltransferase EC 2.3.1.31: homoserine O-acetyltransferase EC 2.3.1.32: lysine N-acetyltransferase EC 2.3.1.33: histidine N-acetyltransferase EC 2.3.1.34: D-tryptophan N-acetyltransferase EC 2.3.1.35: glutamate N-acetyltransferase EC 2.3.1.36: D-amino-acid N-acetyltransferase EC 2.3.1.37: 5-aminolevulinate synthase EC 2.3.1.38: [acyl-carrier-protein] S-acetyltransferase EC 2.3.1.39: [acyl-carrier-protein] S-malonyltransferase EC 2.3.1.40: acyl-[acyl-carrier-protein]—phospholipid O-acyltransferase EC 2.3.1.41: β-ketoacyl-[acyl-carrier-protein] synthase I EC 2.3.1.42: glycerone-phosphate O-acyltransferase EC 2.3.1.43: phosphatidylcholine—sterol O-acyltransferase EC 2.3.1.44: N-acetylneuraminate 4-O-acetyltransferase EC 2.3.1.45: N-acetylneuraminate 7-O(or 9-O)-acetyltransferase EC 2.3.1.46: homoserine O-succinyltransferase EC 2.3.1.47: 8-amino-7-oxononanoate synthase EC 2.3.1.48: histone acetyltransferase EC 2.3.1.49: deacetyl-(citrate-(pro-3S)-lyase) S-acetyltransferase EC 2.3.1.50: serine C-palmitoyltransferase EC 2.3.1.51: 1-acylglycerol-3-phosphate O-acyltransferase EC 2.3.1.52: 2-acylglycerol-3-phosphate O-acyltransferase EC 2.3.1.53: phenylalanine N-acetyltransferase EC 2.3.1.54: formate C-acetyltransferase EC 2.3.1.55: identical to EC 2.3.1.82 EC 2.3.1.56: aromatic-hydroxylamine O-acetyltransferase EC 2.3.1.57: diamine N-acetyltransferase EC 2.3.1.58: 2,3-diaminopropionate N-oxalyltransferase EC 2.3.1.59: gentamicin 2′-N-acetyltransferase EC 2.3.1.60: gentamicin 3′-N-acetyltransferase EC 2.3.1.61: dihydrolipoyllysine-residue succinyltransferase EC 2.3.1.62: 2-acylglycerophosphocholine O-acyltransferase EC 2.3.1.63: 1-alkylglycerophosphocholine O-acyltransferase EC 2.3.1.64: agmatine N4-coumaroyltransferase EC 2.3.1.65: bile acid-CoA:amino acid N-acyltransferase EC 2.3.1.66: leucine N-acetyltransferase EC 2.3.1.67: 1-alkylglycerophosphocholine O-acetyltransferase EC 2.3.1.68: glutamine N-acyltransferase EC 2.3.1.69: monoterpenol O-acetyltransferase EC 2.3.1.70: deleted EC 2.3.1.71: glycine N-benzoyltransferase EC 2.3.1.72: indoleacetylglucose—inositol O-acyltransferase EC 2.3.1.73: diacylglycerol—sterol O-acyltransferase EC 2.3.1.74: chalcone synthase EC 2.3.1.75: long-chain-alcohol O-fatty-acyltransferase EC 2.3.1.76: retinol O-fatty-acyltransferase EC 2.3.1.77: triacylglycerol—sterol O-acyltransferase EC 2.3.1.78: heparan-α-glucosaminide N-acetyltransferase EC 2.3.1.79: maltose O-acetyltransferase EC 2.3.1.80: cysteine-S-conjugate N-acetyltransferase EC 2.3.1.81: aminoglycoside 3-N-acetyltransferase EC 2.3.1.82: aminoglycoside 6′-N-acetyltransferase EC 2.3.1.83: phosphatidylcholine—dolichol O-acyltransferase EC 2.3.1.84: alcohol O-acetyltransferase EC 2.3.1.85: fatty-acid synthase system EC 2.3.1.86: fatty-acyl-CoA synthase system EC 2.3.1.87: aralkylamine N-acetyltransferase EC 2.3.1.88: Now covered by EC 2.3.1.254, EC 2.3.1.255, EC 2.3.1.256, EC 2.3.1.257, EC 2.3.1.258 and EC 2.3.1.259 EC 2.3.1.89: tetrahydrodipicolinate N-acetyltransferase EC 2.3.1.90: β-glucogallin O-galloyltransferase EC 2.3.1.91: sinapoylglucose—choline O-sinapoyltransferase EC 2.3.1.92: sinapoylglucose—malate O-sinapoyltransferase EC 2.3.1.93: 13-hydroxylupinine O-tigloyltransferase EC 2.3.1.94: 6-deoxyerythronolide-B synthase EC 2.3.1.95: trihydroxystilbene synthase EC 2.3.1.96: glycoprotein N-palmitoyltransferase EC 2.3.1.97: glycylpeptide N-tetradecanoyltransferase EC 2.3.1.98: chlorogenate—glucarate O-hydroxycinnamoyltransferase EC 2.3.1.99: quinate O-hydroxycinnamoyltransferase EC 2.3.1.100: [myelin-proteolipid] O-palmitoyltransferase EC 2.3.1.101: formylmethanofuran—tetrahydromethanopterin N-formyltransferase EC 2.3.1.102: N6-hydroxylysine O-acetyltransferase EC 2.3.1.103: sinapoylglucose—sinapoylglucose O-sinapoyltransferase EC 2.3.1.104: The activity is covered by EC 2.3.1.25 EC 2.3.1.105: alkylglycerophosphate 2-O-acetyltransferase EC 2.3.1.106: tartronate O-hydroxycinnamoyltransferase EC 2.3.1.107: deacetylvindoline O-acetyltransferase EC 2.3.1.108: α-tubulin N-acetyltransferase EC 2.3.1.109: arginine N-succinyltransferase EC 2.3.1.110: tyramine N-feruloyltransferase EC 2.3.1.111: mycocerosate synthase EC 2.3.1.112: D-tryptophan N-malonyltransferase EC 2.3.1.113: anthranilate N-malonyltransferase EC 2.3.1.114: 3,4-dichloroaniline N-malonyltransferase EC 2.3.1.115: isoflavone-7-O-β-glucoside 6′′-O-malonyltransferase EC 2.3.1.116: flavonol-3-O-β-glucoside O-malonyltransferase EC 2.3.1.117: 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase EC 2.3.1.118: N-hydroxyarylamine O-acetyltransferase EC 2.3.1.119: Now covered by EC 2.3.1.199, EC 1.1.1.330, EC 4.2.1.134 and EC 1.3.1.93 EC 2.3.1.120: The reaction is due to EC 2.3.1.74 EC 2.3.1.121: 1-alkenylglycerophosphoethanolamine O-acyltransferase EC 2.3.1.122: trehalose O-mycolyltransferase EC 2.3.1.123: dolichol O-acyltransferase EC 2.3.1.124: Already listed as EC 2.3.1.20 EC 2.3.1.125: 1-alkyl-2-acetylglycerol O-acyltransferase EC 2.3.1.126: isocitrate O-dihydroxycinnamoyltransferase EC 2.3.1.127: ornithine N-benzoyltransferase EC 2.3.1.128: now classified as EC 2.3.1.266 and EC 2.3.1.267 EC 2.3.1.129: acyl-[acyl-carrier-protein]—UDP-N-acetylglucosamine O-acyltransferase EC 2.3.1.130: galactarate O-hydroxycinnamoyltransferase EC 2.3.1.131: glucarate O-hydroxycinnamoyltransferase EC 2.3.1.132: glucarolactone O-hydroxycinnamoyltransferase EC 2.3.1.133: shikimate O-hydroxycinnamoyltransferase EC 2.3.1.134: galactolipid O-acyltransferase EC 2.3.1.135: phosphatidylcholine—retinol O-acyltransferase EC 2.3.1.136: polysialic-acid O-acetyltransferase EC 2.3.1.137: carnitine O-octanoyltransferase EC 2.3.1.138: putrescine N-hydroxycinnamoyltransferase EC 2.3.1.139: ecdysone O-acyltransferase EC 2.3.1.140: rosmarinate synthase EC 2.3.1.141: galactosylacylglycerol O-acyltransferase EC 2.3.1.142: glycoprotein O-fatty-acyltransferase EC 2.3.1.143: β-glucogallin—tetrakisgalloylglucose O-galloyltransferase EC 2.3.1.144: anthranilate N-benzoyltransferase EC 2.3.1.145: piperidine N-piperoyltransferase EC 2.3.1.146: pinosylvin synthase EC 2.3.1.147: glycerophospholipid arachidonoyl-transferase (CoA-independent) EC 2.3.1.148: glycerophospholipid acyltransferase (CoA-dependent) EC 2.3.1.149: platelet-activating factor acetyltransferase EC 2.3.1.150: salutaridinol 7-O-acetyltransferase EC 2.3.1.151: 2,3′,4,6-tetrahydroxybenzophenone synthase EC 2.3.1.152: alcohol O-cinnamoyltransferase EC 2.3.1.153: anthocyanin 5-(6′′′-hydroxycinnamoyltransferase) EC 2.3.1.154: Now EC 2.3.1.176 EC 2.3.1.155: acetyl-CoA C-myristoyltransferase EC 2.3.1.156: phloroisovalerophenone synthase EC 2.3.1.157: glucosamine-1-phosphate N-acetyltransferase EC 2.3.1.158: phospholipid:diacylglycerol acyltransferase EC 2.3.1.159: acridone synthase EC 2.3.1.160: vinorine synthase EC 2.3.1.161: lovastatin nonaketide synthase EC 2.3.1.162: taxadien-5α-ol O-acetyltransferase EC 2.3.1.163: 10-hydroxytaxane O-acetyltransferase EC 2.3.1.164: isopenicillin-N N-acyltransferase EC 2.3.1.165: 6-methylsalicylic acid synthase EC 2.3.1.166: 2α-hydroxytaxane 2-O-benzoyltransferase EC 2.3.1.167: 10-deacetylbaccatin III 10-O-acetyltransferase EC 2.3.1.168: dihydrolipoyllysine-residue (2-methylpropanoyl)transferase EC 2.3.1.169: CO-methylating acetyl-CoA synthase EC 2.3.1.170: 6′-deoxychalcone synthase EC 2.3.1.171: anthocyanin 6′′-O-malonyltransferase EC 2.3.1.172: anthocyanin 5-O-glucoside 6′′′-O-malonyltransferase EC 2.3.1.173: flavonol-3-O-triglucoside O-coumaroyltransferase EC 2.3.1.174: 3-oxoadipyl-CoA thiolase EC 2.3.1.175: deacetylcephalosporin-C acetyltransferase EC 2.3.1.176: propanoyl-CoA C-acyltransferase EC 2.3.1.177: 3,5-dihydroxybiphenyl synthase EC 2.3.1.178: diaminobutyrate acetyltransferase EC 2.3.1.179: β-ketoacyl-[acyl-carrier-protein] synthase II EC 2.3.1.180: β-ketoacyl-[acyl-carrier-protein] synthase III EC 2.3.1.181: lipoyl(octanoyl) transferase EC 2.3.1.182: Now covered by EC 2.3.3.21 EC 2.3.1.183: phosphinothricin acetyltransferase EC 2.3.1.184: acyl-homoserine-lactone synthase EC 2.3.1.185: tropine acyltransferase EC 2.3.1.186: pseudotropine acyltransferase EC 2.3.1.187: acetyl-S-ACP:malonate ACP transferase EC 2.3.1.188: ω-hydroxypalmitate O-feruloyl transferase EC 2.3.1.189: mycothiol synthase EC 2.3.1.190: acetoin dehydrogenase EC 2.3.1.191: UDP-3-O-(3-hydroxyacyl)glucosamine N-acyltransferase EC 2.3.1.192: glycine N-phenylacetyltransferase EC 2.3.1.193: tRNAMetcytidine acetyltransferase EC 2.3.1.194: acetoacetyl-CoA synthase EC 2.3.1.195: (Z)-3-hexen-1-ol acetyltransferase EC 2.3.1.196: benzyl alcohol O-benzoyltransferase EC 2.3.1.197: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose 3-N-acetyltransferase EC 2.3.1.198: glycerol-3-phosphate 2-O-acyltransferase EC 2.3.1.199: very-long-chain 3-oxoacyl-CoA synthase EC 2.3.1.200: lipoyl amidotransferase EC 2.3.1.201: UDP-2-acetamido-3-amino-2,3-dideoxy-glucuronate N-acetyltransferase EC 2.3.1.202: UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine N-acetyltransferase EC 2.3.1.203: UDP-N-acetylbacillosamine N-acetyltransferase EC 2.3.1.204: octanoyl-[GcvH]:protein N-octanoyltransferase EC 2.3.1.205: fumigaclavine B O-acetyltransferase EC 2.3.1.206: 3,5,7-trioxododecanoyl-CoA synthase EC 2.3.1.207: β-ketodecanoyl-[acyl-carrier-protein] synthase EC 2.3.1.208: 4-hydroxycoumarin synthase EC 2.3.1.209: dTDP-4-amino-4,6-dideoxy-D-glucose acyltransferase EC 2.3.1.210: dTDP-4-amino-4,6-dideoxy-D-galactose acyltransferase EC 2.3.1.211: bisdemethoxycurcumin synthase EC 2.3.1.212: benzalacetone synthase EC 2.3.1.213: cyanidin 3-O-(6-O-glucosyl-2-O-xylosylgalactoside) 6′′′-O-hydroxycinnamoyltransferase EC 2.3.1.214: pelargonidin 3-O-(6-caffeoylglucoside) 5-O-(6-O-malonylglucoside) 4′′′-malonyltransferase EC 2.3.1.215: anthocyanin 3-O-glucoside 6-O-hydroxycinnamoyltransferase EC 2.3.1.216: 5,7-dihydroxy-2-methylchromone synthase EC 2.3.1.217: curcumin synthase EC 2.3.1.218: phenylpropanoylacetyl-CoA synthase EC 2.3.1.219: demethoxycurcumin synthase EC 2.3.1.220: 2,4,6-trihydroxybenzophenone synthase EC 2.3.1.221: noranthrone synthase EC 2.3.1.222: phosphate propanoyltransferase EC 2.3.1.223: 3-oxo-5,6-didehydrosuberyl-CoA thiolase EC 2.3.1.224: acetyl-CoA-benzylalcohol acetyltransferase EC 2.3.1.225: protein S-acyltransferase EC 2.3.1.226: carboxymethylproline synthase EC 2.3.1.227: GDP-perosamine N-acetyltransferase EC 2.3.1.228: isovaleryl-homoserine lactone synthase EC 2.3.1.229: 4-coumaroyl-homoserine lactone synthase EC 2.3.1.230: 2-heptyl-4(1H)-quinolone synthase EC 2.3.1.231: tRNAPhe {7-[3-amino-3-(methoxycarbonyl)propyl]wyosine37 -N}-methoxycarbonyltransferase EC 2.3.1.232: methanol O-anthraniloyltransferase EC 2.3.1.233: 1,3,6,8-tetrahydroxynaphthalene synthase EC 2.3.1.234: N6-L-threonylcarbamoyladenine synthase EC 2.3.1.235: tetracenomycin F2 synthase EC 2.3.1.236: 5-methylnaphthoic acid synthase EC 2.3.1.237: neocarzinostatin naphthoate synthase EC 2.3.1.238: monacolin J acid methylbutanoate transferase EC 2.3.1.239: 10-deoxymethynolide synthase EC 2.3.1.240: narbonolide synthase EC 2.3.1.241: Kdo2-lipid IVA lauroyltransferase EC 2.3.1.242: Kdo2-lipid IVA palmitoleoyltransferase EC 2.3.1.243: lauroyl-Kdo2-lipid IVA myristoyltransferase EC 2.3.1.244: 2-methylbutanoate polyketide synthase EC 2.3.1.245: 3-hydroxy-5-phosphooxypentane-2,4-dione thiolase EC 2.3.1.246: 3,5-dihydroxyphenylacetyl-CoA synthase EC 2.3.1.247: 3-keto-5-aminohexanoate cleavage enzyme EC 2.3.1.248: spermidine disinapoyl transferase EC 2.3.1.249: spermidine dicoumaroyl transferase EC 2.3.1.250: [Wnt protein] O-palmitoleoyl transferase EC 2.3.1.251: lipid IVA palmitoyltransferase EC 2.3.1.252: mycolipanoate synthase EC 2.3.1.253: phloroglucinol synthase EC 2.3.1.254: N-terminal methionine Nα-acetyltransferase NatB EC 2.3.1.255: N-terminal amino-acid Nα-acetyltransferase NatA EC 2.3.1.256: N-terminal methionine Nα-acetyltransferase NatC EC 2.3.1.257: N-terminal L-serine Nα-acetyltransferase NatD EC 2.3.1.258: N-terminal methionine Nα-acetyltransferase NatE EC 2.3.1.259: N-terminal methionine Nα-acetyltransferase NatF EC 2.3.1.260: tetracycline polyketide synthase EC 2.3.1.261: (4-hydroxyphenyl)alkanoate synthase EC 2.3.1.262: anthraniloyl-CoA anthraniloyltransferase EC 2.3.1.263: 2-amino-4-oxopentanoate thiolase EC 2.3.1.264: β-lysine N6-acetyltransferase EC 2.3.1.265: phosphatidylinositol dimannoside acyltransferase EC 2.3.1.266: [ribosomal protein S18]-alanine N-acetyltransferase EC 2.3.1.267: [ribosomal protein S5]-alanine N-acetyltransferase EC 2.3.1.268: ethanol O-acetyltransferase EC 2.3.1.269: apolipoprotein N-acyltransferase EC 2.3.1.270: lyso-ornithine lipid O-acyltransferase EC 2.3.1.271: L-glutamate-5-semialdehyde N-acetyltransferase EC 2.3.1.272: 2-acetylphloroglucinol acetyltransferase EC 2.3.1.273: diglucosylglycerate octanoyltransferase EC 2.3.1.274: phosphate acyltransferase EC 2.3.1.275: acyl phosphate:glycerol-3-phosphate acyltransferase EC 2.3.1.276: galactosamine-1-phosphate N-acetyltransferase EC 2.3.1.277: 2-oxo-3-(phosphooxy)propyl 3-oxoalkanoate synthase EC 2.3.1.278: mycolipenoyl-CoA—2-(long-chain-fatty acyl)-trehalose mycolipenoyltransferase EC 2.3.1.279: long-chain-acyl-CoA—trehalose acyltransferase EC 2.3.1.280: (aminoalkyl)phosphonate N-acetyltransferase EC 2.3.1.281: 5-hydroxydodecatetraenal polyketide synthase EC 2.3.1.282: phenolphthiocerol/phthiocerol/phthiodiolone dimycocerosyl transferase EC 2.3.1.283: 2′-acyl-2-O-sulfo-trehalose (hydroxy)phthioceranyltransferase EC 2.3.1.284: 3′-(hydroxy)phthioceranyl-2′-palmitoyl(stearoyl)-2-O-sulfo-trehalose (hydroxy)phthioceranyltransferase EC 2.3.1.285: (13S,14R)-1,13-dihydroxy-N-methylcanadine 13-O-acetyltransferase EC 2.3.1.286: protein acetyllysine N-acetyltransferase EC 2.3.1.287: phthioceranic/hydroxyphthioceranic acid synthase EC 2.3.1.288: 2-O-sulfo trehalose long-chain-acyltransferase EC 2.3.1.289: aureothin polyketide synthase system EC 2.3.1.290: spectinabilin polyketide synthase system EC 2.3.1.291: sphingoid base N-palmitoyltransferase EC 2.3.1.292: (phenol)carboxyphthiodiolenone synthase EC 2.3.1.293: meromycolic acid 3-oxoacyl-(acyl carrier protein) synthase I EC 2.3.1.294: meromycolic acid 3-oxoacyl-(acyl carrier protein) synthase II EC 2.3.1.295: mycoketide-CoA synthase EC 2.3.1.296: ω-hydroxyceramide transacylase EC 2.3.1.297: very-long-chain ceramide synthase EC 2.3.1.298: ultra-long-chain ceramide synthase EC 2.3.1.299: sphingoid base N-stearoyltransferase EC 2.3.1.300: branched-chain β-ketoacyl-[acyl-carrier-protein] synthase EC 2.3.1.301: mycobacterial β-ketoacyl-[acyl carrier protein] synthase III EC 2.3.1.302: hydroxycinnamoyl-CoA:5-hydroxyanthranilate N-hydroxycinnamoyltransferase EC 2.3.1.303: α-L-Rha-(1→2)-α-D-Man-(1→2)-α-D-Man-(1→3)-α-D-Gal-PP-Und 2IV-O-acetyltransferase EC 2.3.1.304: poly[(S)-3-hydroxyalkanoate] polymerase
== History == In 1998, the University of Michigan formed a commission to create a vision for the future of the life sciences at the university. In response to the commission's recommendations, in 1999, the Regents of the University of Michigan unanimously approved the construction of the Life Sciences Institute, noting that "the creation of a life sciences institute will eliminate the structural barriers to a shared research and learning experience that will be valuable for both basic and applied research." Initial funding of $100 million was provided for the creation of wet lab space, in addition to the $130 million for the endowment and startup costs. The first faculty members moved into the building and opened their labs in September 2003, and the institute opened in May 2004. That same year, the institute's first two research cores opened, supporting high-throughput screening and structural biology research : the Center for Structural Biology and the Center for Chemical Genomics. The cryo-electron microscopy facility opened in 2009, expanding the institute's structural biology capabilities. In 2018, with support from the U-M Biosciences Initiative, the institute began expanding the cryo-EM program and also launched its Natural Products Discovery Core. In 2021, the building that houses the institute was renamed Mary Sue Coleman Hall, in honor of President Emerita Mary Sue Coleman.
Estrogen also causes the laying down of fat in the development of the secondary sex characteristics. This contributes to the maturation of the vulva with increases in the size of the mons pubis, and the labia majora and the enlargement of the labia minora.
Sources: en.wikipedia.org
=== Associated conditions === Sjögren's disease is associated with a number of other medical conditions, many of which are autoimmune or rheumatic disorders, such as celiac disease, fibromyalgia, systemic lupus erythematosus (lupus), autoimmune thyroiditis, multiple sclerosis and spondyloarthropathy, and several malignancies, principally non-Hodgkin lymphoma. Sjogren's is the second most common cause of dysautonomia.
=== Attribution === Portions of the text of this article originate from NIH Publication No. 02-4806, a public domain resource. "What I need to know about Prostate Problems". National Institutes of Health. 2002-06-01. No. 02-4806. Archived from the original on 2002-06-01. Retrieved 2011-01-24.
==== Rhizomes ==== The rhizomes are 60–14 cm (23.6–5.5 in) long, 0.5–2.5 cm (0.20–0.98 in) in diameter, yellowish white to yellowish brown, smooth, and with nodes and internodes. Lotus root is a moderate-calorie root vegetable (100 g of root stem provides about 74 calories) and is composed of several vitamins, minerals, and nutrients: 83.80% water, 0.11% fat, 1.56% reducing sugar, 0.41% sucrose, 2.70% crude protein, 9.25% starch, 0.80% fibre, 0.10% ash and 0.06% calcium. 100 g of root provides 44 mg of vitamin C or 73% of daily recommended values (RDA). Lotus rhizome and its extracts have shown diuretic, psychopharmacological, anti-diabetic, anti-obesity, hypoglycemic, antipyretic and antioxidant activities.
=== Tools === Paleolithic humans made tools of stone, bone (primarily of deer), and wood. The early Paleolithic hominins, Australopithecus, were the first users of stone tools. Excavations in Gona, Ethiopia, have produced thousands of artifacts, and through radioisotopic dating and magnetostratigraphy the sites can be firmly dated to 2.6 million years ago. Evidence shows these early hominins intentionally selected raw stone with good flaking qualities and chose appropriately sized stones for their needs to produce sharp-edged tools for cutting. The earliest Paleolithic stone tool industry, the Oldowan, began around 2.6 million years ago. It produced tools such as choppers, burins, and stitching awls. It was completely replaced around 250,000 years ago by the more complex Acheulean industry, which was first conceived by Homo ergaster around 1.8–1.65 million years ago. The Acheulean implements completely vanish from the archaeological record around 100,000 years ago and were replaced by more complex Middle Paleolithic tool kits such as the Mousterian and the Aterian industries. Lower Paleolithic humans used a variety of stone tools, including hand axes and choppers. Although they appear to have used hand axes often, there is disagreement about their use. Interpretations range from cutting and chopping tools, to digging implements, to flaking cores, to the use in traps, and as a purely ritual significance, perhaps in courting behavior. William H.
=== Kuwaiti resistance movement === Kuwaitis founded a local armed resistance movement following the Iraqi occupation of Kuwait. The Kuwaiti resistance's casualty rate far exceeded that of the coalition military forces and Western hostages. The resistance predominantly consisted of ordinary citizens who lacked any form of training and supervision.
Sources: en.wikipedia.org
Common methods include HPLC with ultraviolet detection and LC-MS/MS. These techniques separate NMN from related nucleotides and quantify it by retention time and mass-to-charge ratio.
Low temperature and low moisture slow hydrolysis and other degradation reactions. Desiccants and sealed containers reduce exposure to water vapor and oxygen.
It typically reports identity, purity, water content, and selected impurities. The exact panel depends on the supplier, product grade, and intended application.
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.